{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:33:50Z","timestamp":1768289630278,"version":"3.49.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ejps.2021.105725","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:33:40Z","timestamp":1611056020000},"page":"105725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design and evaluation of pharmaceutical availability, stability and quality of modified viscosity eye drops with choline salicylate"],"prefix":"10.1016","volume":"159","author":[{"given":"Katarzyna B.","family":"Wr\u00f3blewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szymon","family":"Plewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"D\u0142ugaszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Muszalska-Kolos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105725_bib0001","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1208\/s12248-008-9024-9","article-title":"Topical ocular delivery of NSAIDs","volume":"10","author":"Ahuja","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.ejps.2021.105725_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/861904","article-title":"Ophthalmic Drug Dosage Forms: Characterisation and Research Methods","author":"Baranowski","year":"2014","journal-title":"The Scientific World Journal"},{"key":"10.1016\/j.ejps.2021.105725_bib0003","first-page":"2338","article-title":"Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells","volume":"42","author":"Chin","year":"2001","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejps.2021.105725_bib0004","first-page":"15","article-title":"Topical acetylsalicylic acid in the treatment of allergic pollinosic conjunctivitis","volume":"2","author":"Ciprandi","year":"1992","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.ejps.2021.105725_bib0005","unstructured":"European Pharmacopoeia, 10th ed.; Council of Europe: Strasbourg, France, 2019; p. 191."},{"key":"10.1016\/j.ejps.2021.105725_bib0006","series-title":"(Polish Pharmacopoeia), Urz\u0105d Rejestracji Produkt\u00f3w Leczniczych","first-page":"4409","author":"Farmakopea Polska","year":"2017"},{"key":"10.1016\/j.ejps.2021.105725_bib0007","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0039-6257(92)90095-B","article-title":"Cycle-oxygenase inhibitors in ophthalmology","volume":"36","author":"Flach","year":"1992","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.ejps.2021.105725_bib0008","first-page":"221","article-title":"Topical aspirin provides protection against galactosemic cataract","volume":"45","author":"Gupta","year":"1997","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.ejps.2021.105725_bib0009","series-title":"Quality Control Department","year":"2017"},{"key":"10.1016\/j.ejps.2021.105725_bib0010","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0014-2999(94)90740-4","article-title":"Fibroblast growth-promoting activity in proliferative vitreoretinopathy: antagonism by acetylsalicylic acid","volume":"262","author":"K\u00e4hler","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105725_bib0011","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.survophthal.2009.07.005","article-title":"Nonsteroidal anti-inflammatory drugs in ophthalmology","volume":"55","author":"Kim","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ejps.2021.105725_bib0012","first-page":"29","article-title":"Wp\u0142yw miejscowych niesteroidowych lek\u00f3w przeciwzapalnych na przedni i tylny odcinek oka (Effects of topical non-steroidal anti-inflammatory drugs on the anterior and posterior segment of the eye, in polish)","volume":"2","author":"Mrukawa-Kominek","year":"2012","journal-title":"Okulistyka po Dyplomie"},{"key":"10.1016\/j.ejps.2021.105725_bib0013","unstructured":"Salicylan choliny - Medycyna Praktyczna (in polish): https:\/\/www.mp.pl\/pacjent\/leki\/leki\/subst.html?id=713. (accessed 22 June 2019 )."},{"key":"10.1016\/j.ejps.2021.105725_bib0014","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000068563","article-title":"Topical nonsteroidal anti-inflammatory therapy in ophthalmology","volume":"217","author":"Schalnus","year":"2003","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ejps.2021.105725_bib0015","first-page":"1","article-title":"Nonsteroidal anti-inflammatory drugs for retinal disease","author":"Schoenberger","year":"2013","journal-title":"Int. J. Inflam"},{"key":"10.1016\/j.ejps.2021.105725_bib0016","series-title":"Twelfth Edition an encyclopedia of chemicals, drugs and biologicals","first-page":"370","year":"1996"},{"key":"10.1016\/j.ejps.2021.105725_bib0017","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1039\/C5GC00416K","article-title":"Bioactive transparent films based on polysaccharides and cholinium carboxylate ionic liquids","volume":"17","author":"Tom\u00e9","year":"2015","journal-title":"Green Chem"},{"key":"10.1016\/j.ejps.2021.105725_bib0018","first-page":"3299","article-title":"Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration","volume":"43","author":"Voigt","year":"2002","journal-title":"IOVS"},{"key":"10.1016\/j.ejps.2021.105725_bib0019","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jsps.2014.11.009","article-title":"Characterization of new eye drops with choline salicylate and assessment of their irritancy by in vitro short time exposure","volume":"23","author":"Wroblewska","year":"2014","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ejps.2021.105725_bib0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3390\/molecules25010051","article-title":"Choline salicylate analysis: chemical stability and degradation product identification","volume":"25","author":"Wr\u00f3blewska","year":"2020","journal-title":"Molecules"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:56:44Z","timestamp":1760529404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":20,"alternative-id":["S0928098721000270"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105725","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and evaluation of pharmaceutical availability, stability and quality of modified viscosity eye drops with choline salicylate","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105725"}}